Lantern Pharma Q3 2022 net loss improves to $2.3M; cash $57.8M, pipeline on track

Lantern Pharma Inc.

2023-Q3 EPS reported -$1.00

Net loss of $2.3M ($0.21/shr) vs $4.1M ($0.36/shr) in Q3 2021; R&D expenses fell to $0.7M.
Cash, equivalents and marketable securities $57.8M as of Sep 30, 2022; cash runway into 2025.
Harmonic Phase 2 trial (LP-300) activated first two US sites; new U.S. patent issued for LP-300 through 2032.
IND-enabling studies for LP-184 and LP-284 expected complete Q1 2023; Phase 1 launches targeted H1 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lantern Pharma Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30 , 2022.

View on SEC.gov

Browse all earnings releases →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-030817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.